Royalty Pharma Declares Fourth Quarter 2024 Dividend
Royalty Pharma plc (Nasdaq: RPRX) has announced its dividend for the fourth quarter of 2024. The company's board of directors has approved a dividend payment of $0.21 per Class A ordinary share. This dividend will be distributed on December 10, 2024, to shareholders who are on record as of the close of business on November 15, 2024. The announcement demonstrates Royalty Pharma's commitment to returning value to its shareholders through regular dividend payments.
Royalty Pharma plc (Nasdaq: RPRX) ha annunciato il suo dividendo per il quarto trimestre del 2024. Il consiglio di amministrazione dell'azienda ha approvato un pagamento di dividendo di $0,21 per azione ordinaria di Classe A. Questo dividendo sarà distribuito il 10 dicembre 2024 agli azionisti registrati alla chiusura degli affari del 15 novembre 2024. L'annuncio dimostra l'impegno di Royalty Pharma nel restituire valore ai suoi azionisti attraverso pagamenti di dividendi regolari.
Royalty Pharma plc (Nasdaq: RPRX) ha anunciado su dividendo para el cuarto trimestre de 2024. La junta directiva de la compañía ha aprobado un pago de dividendo de $0.21 por acción ordinaria de Clase A. Este dividendo se distribuirá el 10 de diciembre de 2024 a los accionistas que estén registrados al cierre de operaciones del 15 de noviembre de 2024. El anuncio demuestra el compromiso de Royalty Pharma de devolver valor a sus accionistas a través de pagos de dividendos regulares.
Royalty Pharma plc (Nasdaq: RPRX)는 2024년 4분기 배당금을 발표하였습니다. 회사 이사회는 클래스 A 보통주 1주당 $0.21의 배당금 지급을 승인하였습니다. 이 배당금은 2024년 12월 10일에 배당되며, 2024년 11월 15일 업무 종료 시 점유하고 있는 주주에게 지급될 것입니다. 이번 발표는 Royalty Pharma가 정기적인 배당금 지급을 통해 주주에게 가치를 환원하겠다는 의지를 보여줍니다.
Royalty Pharma plc (Nasdaq: RPRX) a annoncé son dividende pour le quatrième trimestre 2024. Le conseil d'administration de la société a approuvé un paiement de dividende de 0,21 $ par action ordinaire de Classe A. Ce dividende sera distribué le 10 décembre 2024, aux actionnaires qui sont enregistrés à la clôture des opérations du 15 novembre 2024. L'annonce démontre l'engagement de Royalty Pharma à restituer de la valeur à ses actionnaires à travers des paiements de dividendes réguliers.
Royalty Pharma plc (Nasdaq: RPRX) hat seine Dividende für das vierte Quartal 2024 bekannt gegeben. Der Vorstand des Unternehmens hat eine Dividendenzahlung von 0,21 $ pro Stammaktie der Klasse A genehmigt. Diese Dividende wird am 10. Dezember 2024 an Aktionäre ausgezahlt, die zum Ende des Geschäftstags am 15. November 2024 registriert sind. Die Ankündigung zeigt das Engagement von Royalty Pharma, seinen Aktionären durch regelmäßige Dividendenzahlungen Wert zurückzugeben.
- Consistent dividend payment indicates financial stability
- Dividend of $0.21 per share provides income for investors
- None.
Insights
The announcement of Royalty Pharma's Q4 2024 dividend of
While the dividend amount remains unchanged, it's important to note that Royalty Pharma's business model, focused on acquiring biopharmaceutical royalties, typically provides a steady cash flow. This allows for reliable dividend payments, which can be appealing to income-focused investors. However, the lack of dividend growth might be a concern for some, as it doesn't keep pace with potential inflation.
The ex-dividend date, which is typically one business day before the record date of November 15, 2024, is important for investors looking to qualify for this dividend. Overall, this news reinforces Royalty Pharma's commitment to shareholder returns but doesn't signal any significant changes in the company's financial position or strategy.
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of
The dividend will be paid on December 10, 2024, to shareholders of record at the close of business on November 15, 2024.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 16 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
What is the dividend amount for Royalty Pharma (RPRX) in Q4 2024?
When will Royalty Pharma (RPRX) pay its Q4 2024 dividend?
What is the record date for Royalty Pharma's (RPRX) Q4 2024 dividend?
Has Royalty Pharma's (RPRX) board of directors approved the Q4 2024 dividend?
